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Introduction
Nucleoside analogues such as cytarabine (Ara-C) and gemcitabine (dFdC) are antimetabolic 2′-deoxycytidine (dCyd) analogues administered therapeutically to patients with malignant tumors (Fig.  1) . The antitumor nucleoside 2′-C-cyano-2′-deoxy-1-β-Darabinofuranosylcytosine (CNDAC) exerts potent antitumor activity against various human tumor cells in vitro and in vivo (Tanaka et al., 1992 , Azuma et al., 1993 and is expected to have an excellent clinical efficacy. Currently, a clinical phase study involving CNDAC is underway in the USA.
CNDAC is transported into cells by nucleoside-specific transporters and monophosphorylated by dCyd kinase (dCK). Subsequently, it undergoes enzymatic phosphorylation and is converted to a triphosphate form. The triphosphate group of CNDAC inhibits DNA chain elongation after being incorporated into the DNA strand as a terminator and induces breakage of the DNA strand at its 3′-diester bond (Azuma et al., 1993; Matsuda and Sasaki, 2004) . After incorporation into cells, dFdC and Ara-C undergo deamination by cytidine deaminase (CDA) and are inactivated conversion to their uracil metabolites. In contrast, CNDAC is reported to be a poor substrate for mouse CDA, but the reactivity of CNDAC for human CDA has not been yet been investigated in detail.
Human CDA (EC 3.5.4.5) is a 146-amino acid protein (16.1 kDa) and generates Urd or dUrd by hydrolyzing the 4-amino group of Cyd and dCyd (Vincenzetti et al., 1996) . In humans, CDA activity has been reported in tumor cells as well as in normal tissues, including the liver, spleen, intestinal mucosa, and lung, with particularly high activity in the liver and spleen (Camiener and Smith, 1965) . The CDA gene is located on chromosome 1 (1p36.2-p35, 31 kb) and is composed of four exons (Saccone et al., 1994) . Three single nucleotide polymorphisms have been previously reported at nucleotide position 79 (A to C), position 208 (G to A), and position 435 (T to C) in the amino acid-coding region of the human CDA gene (Kirch et al., 1998 , Yue et al., 2003 . Some studies have demonstrated that CDA gene This article has not been copyedited and formatted. The final version may differ from this version. (Sugiyama et al., 2007 .
Serum CDA activity was recently reported to correlate with toxicity after gemcitabine chemotherapy, but no genotype-to-phenotype relationships were observed (Ciccolini et al., 2010) . However, the relationship between CDA activity and sensitivity to dFdC and CNDAC in cancer cells remains unclear.
In this study, we established a recombinant human CDA (rhCDA) expression system and compared the substrate reactivity of dCyd analogues, including dFdC and CNDAC, in
rhCDA. In addition, we established a stable cell line overexpressing human CDA by introducing a cDNA expression vector into human solid tumor cells (gastric cancer TMK-1 cells) and compared their susceptibility to various types of antitumor dCyd analogues in vitro and in vivo to further explore the significance of CDA as a factor regulating susceptibility.
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Methods
Animals
We used 6-week-old female ICRnu/nu nude mice (Charles River Japan, Kanagawa, Japan). 
Cell culture and materials
Ara-C was purchased from Yamasa Shoyu (Choshi, Japan). CNDAC and gemcitabine were kindly provided by Taiho (Saitama, Japan). Anti-human CDA monoclonal antibody was produced using rhCDA as antigen. Human gastric tumor TMK-1, MKN-45, NUGC-3, and NKPS cells and human fibrosarcoma tumor HT-1080 cells were cultured in RPMI-1640 medium (Nissui Pharmaceutical, Osaka, Japan) containing 10% fetal bovine serum (GIBCO, Grand Island, NY) and 50 µg/ml kanamycin at 37°C in a humidified atmosphere.
Production of human CDA protein
The full coding sequence of human CDA cDNA from HT-1080 cells was amplified by PCR using the sense primer 5′-GTCTAGGAGAGGAGCCGCAATCGTGTCT-3′ and antisense primer 5′-AAGTTGCTCGGAACAGGATAGAACC-3′. The CDA cDNA was cloned into the pcDNA4-His-Max TOPO vector (Invitrogen, Carlsbad, CA), which was then digested with CDA activity of cell-lysate, serum, and protein extract samples was measured as previously described (Zhang et al., 1999) . Sample was added to a reaction mixture (100 µl), containing 500 µM Cyd or antitumor dCyd analogues in potassium phosphate buffer (pH 7.4). The mixture was incubated at 37°C for 30 min, followed by HPLC analysis. The mixture was incubated at 95°C for 5 min to inactivate CDA. The mixture was then centrifuged at 15,000 rpm for 10 min, and the supernatant was applied to reversed-phase column chromatography (CAPCELL PAK C18 UG120,φ4.6×250 mm, Shiseido, Tokyo, Japan). The elution was conducted at 0.5 ml/min using methanol:water (10:90), and Cyd and Urd were monitored at 254 nm. The retention time was approximately 7 min for Cyd and 9 min for Urd.
Establishment of CDA-overexpressing cancer cell line
To establish a stable cell line overexpressing human CDA, the full coding sequence of human 
In vitro chemosensitivity
In vitro cytotoxicity was examined using a modified tetrazolium-based semi-automatic colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma, St. Louis, MO) as previously described (Carmichael et al., 1987 , Tanaka et al., 1992 . Cancer cells were plated in a 96-well plate at a density of 5 × 10 3 cells/well. dCyd analogues were dissolved and diluted with distilled water for injection (Otsuka Pharmaceutical, Tokyo, Japan). Serial dilutions of dCyd analogues were added in each well, and the plate was incubated at 37°C for 72 h. After incubation, 25 µl of MTT solution (5 mg/ml in PBS) was added in the culture medium, and the plate was incubated at 37°C for an additional 4 h. The cytotoxicity was calculated by applying the following formula: % of cell growth inhibition = [1 -(T/C)] × 100, where C is the mean A 540 of the control group and T is that of the treated group. The IC 50 value was measured graphically from the dose-response curve with at least three drug concentration points.
In vivo chemosensitivity in xenograft model
TMK-1/CDA or TMK-1/pcDNA4 cells (2 × 10 7 ) were subcutaneously transplanted into 6-week-old female ICRnu/nu nude mice on day 0. CNDAC was intraperitoneally administered at a dose of 7 mg/kg (5 day/week × 2) beginning on day 6. Tumor size was measured and This article has not been copyedited and formatted. The final version may differ from this version. Among the dCyd analogues, K m values were observed in the following order: Ara-C (0.299 mM) < dFdC (0.594 mM) < CNDAC (5.14 mM) ( Table 1 ). V max /K m values, which indicate the efficiency of reactions, for the natural substrates Cyd and dCyd were higher than those of dCyd analogues. In addition, dFdC (0.0167) and Ara-C (0.0185) were found to have nearly the same reactivity; in comparison, the reaction efficiency of CNDAC (0.0014) to rhCDA was more than 10 times lower than those of Ara-C and dFdC.
CDA activity and protein expression in transfected cells
To determine the significance of CDA as a factor regulating chemosensitivity, we introduced a human CDA expression vector into TMK-1 cells to generate cell lines stably overexpressing CDA. The expression of CDA protein in the transfected cells was analyzed by western blot analysis, and we observed almost no CDA protein expression in TMK-1/mock cells ( Fig. 2A) .
Conversely, strong CDA protein expression was observed in the cell lysates and conditioned medium of TMK-1/CDA cells transfected with the CDA expression vector. In addition, we investigated the time course of secretion of CDA protein in TMK-1/CDA cells. The CDA protein was found to be released into conditioned medium, and the amount of secreted CDA protein gradually increased from 4 h to 24 h (Fig. 2B ). Compared to TMK-1/mock cells, CDA activity was distinctly enhanced in TMK-1/CDA cells (Fig. 2C) ; therefore, we were able to confirm that the cells overexpressed active CDA. The CDA activity of lysate from TMK-1/CDA cells was 16.6 pmol/min (Fig. 2D) .
Expression of CDA in human gastric cancer cell lines
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In vitro chemosensitivity of CDA-overexpressing cells
We examined the cytotoxicity of dCyd analogues on TMK-1/CDA and on TMK-1/mock cells. Compared to TMK-1/mock cells, TMK-1/CDA cells showed a substantially reduced susceptibility to Ara-C, dFdC, and CNDAC (Fig. 4) . The IC 50 value for Ara-C was 108 times higher than in TMK-1/mock cells, the IC 50 value for dFdC was 63 times higher, and that of CNDAC increased to 101 times higher. Resistance to antitumor dCyd analogues was confirmed in CDA-overexpressing cells ( Table 2) .
Chemosensitivity of CDA-overexpressing TMK-1 cells in a xenograft model
We investigated the chemosensitivity of TMK-1/CDA and TMK-1/mock cells to CNDAC in vivo using the xenograft model. CNDAC was intraperitoneally administered at a dose of 7 mg/kg (5 d/week × 2) beginning 6 days after transplantation. Fig. 5 shows the tumor growth curve. CNDAC showed significant antitumor activity against TMK-1/mock cells. In contrast, no significant difference in tumor growth was observed between control and CNDAC-treated TMK-1/CDA cells. To confirm the presence of human CDA protein in the serum of mice transplanted with TMK-1/CDA cells, we performed western blot analysis using a monoclonal antibody against human CDA. The transplanted TMK-1/CDA cells produced human CDA protein even 28 days after transplantation, but human CDA protein was not detectable in mice transplanted with TMK-1/mock cells (Fig. 6) . Thus, the human CDA produced was found to be released into the serum of mice.
Discussion
During the period between the 1970s to the 1980s, several clinical studies were performed on the combined use of a cytidine deaminase inhibitor-tetrahydrouridine (THU)-with Ara-C in patients with acute leukemia. It was reported that THU increased serum Ara-C levels and the response rates achieved with the combination were comparable to those achieved with high dose Ara-C. 5-Fluoro-2'-deoxycytidine (FdCyd) is a DNA methyltransferase inhibitor and is rapidly converted to its uracil form 5-fluoro-2'-deoxyuridine by CDA in vivo.
Recently, a phase I study on FdCyd and THU was conducted in patients with advanced solid tumors in order to determine the maximum tolerated dose of FdCyd and to determine the methylation status of p16 and other genes relevant to neoplasias in NCI. CDA is considered not only a predictive marker of chemosensitivity to antitumor dCyd analogues but also a useful target for biochemical modulation of these analogues.
In this study, we established a stable human CDA-expressing cell line, conducted a comparative examination of its chemosensitivity to various antitumor dCyd analogues, and examined the relationship between CDA expression and chemosensitivity. First, we examined the substrate reactivity of antitumor dCyd analogues to rhCDA and found that dFdC and Ara-C had nearly the same reactivity, whereas the reactivity of CNDAC was more than 10 times lower. Adjusting V max /K m = 1 for dFdC, its value was 0.90 for Ara-C and 0.08 for CNDAC.
We then examined the cytotoxicity of 2′-dCyd analogues on cancer cells using TMK-1/CDA cells in vitro. CDA overexpression led to reduced susceptibility to antitumor dCyd analogues.
However, no clear correlation was observed between the increased IC 50 value and the degree of substrate reactivity to rhCDA. Ara-C and dFdC demonstrated comparable degrees of substrate reactivity, but the rate of decrease in the cytotoxicity against CDA-overexpressing cell lines was more pronounced with Ara-C. Although the reactivity of CNDAC to CDA was more than 10 times lower than that of other dCyd analogues, the rate of decrease in the cytotoxicity was relatively greater, as summarized in 13 cytotoxicity of dFdC is thought to be due its faster initial uptake into cells than that of Ara-C.
Because it has a high affinity and substrate reactivity to dCK (Heinemann et al. 1988) , it enters the cell rapidly, becomes phosphorylated, and is converted into dFdCTP; thus, it is less exposed to intra-and extracellular CDA than Ara-C. However, the velocity of the uptake of furthermore, the substrate reactivity of CNDAC to dCK is also as low as 1/20 (Uchida et al., 1999) . Thus, CNDAC can be metabolized by CDA on many occasions in and outside the cells because of its low efficiency for membrane transport and monophosphorylation, even if it has low substrate reactivity to CDA. These results suggest that the intracellular transport capability of nucleosidic transporters and the activities of both dCK and CDA are important factors that regulate susceptibility to 2′-dCyd analogues, and that their reciprocal balance determines chemosensitivity.
Next, to determine the effect of the antitumor activity of 2′-dCyd analogues in vivo, we conducted a comparative study of the efficacy of CNDAC using a nude mouse xenograft model transplanted subcutaneously with TMK-1/CDA or TMK-1/mock cells. An apparent resistance to the antitumor effect of CNDAC was observed in the cells overexpressing CDA.
Leukemic cells have been reported to release CDA into their culture medium in vitro, which subsequently influences their chemosensitivity to Ara-C (Kawai et al., 1994) . In addition, in the treatment of leukemia, Ara-C is thought to be rapidly metabolized and inactivated by CDA on the basis of its presence in the liver and blood. In this study, CDA-overexpresing cells and some gastric cancer cell lines also released CDA into their culture medium in vitro.
We further confirmed that human CDA protein was present in the serum of nude mice transplanted with TMK-1/CDA cells, indicating that the CDA released by tumor cells flows into the blood. As mentioned earlier, CNDAC has a low substrate reactivity to CDA.
However, transportation of CNDAC into cells is relatively slow, and thus in that environment, it is thought to be easily exposed to extracellular CDA, such as that in blood and extracellular Reaction mixture (100 µl) containing 10 µg/ml cell lysate and 0.5 mM Cyd in potassium phosphate buffer was incubated at 37ºC for 30 min. CDA activity was determined by the amount of deaminated products (Urd) per min. The values represent means ± S.D. Fig. 3 Protein expression of CDA in human gastric cancer cell lines. Cells were plated at a density of 1 × 10 6 cells/6-cm dish. After 24 h, the medium was exchanged for serum-free medium, and the cells were incubated for 24 h. Conditioned medium was concentrated 150-fold using a gel-filtration spin column. Ten micrograms of cell lysate and 15 µl of concentrated medium were used for western blot analysis. The values represent means ± S.E. 
